SENS Stock Overview
A medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Senseonics Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.32 |
| 52 Week High | US$0.75 |
| 52 Week Low | US$0.28 |
| Beta | 0.80 |
| 11 Month Change | -9.42% |
| 3 Month Change | -20.04% |
| 1 Year Change | -46.27% |
| 33 Year Change | -90.30% |
| 5 Year Change | -70.62% |
| Change since IPO | -90.24% |
Recent News & Updates
Recent updates
Shareholder Returns
| SENS | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 6.0% | -0.4% | -1.0% |
| 1Y | -46.3% | 20.3% | 30.3% |
Return vs Industry: SENS underperformed the US Medical Equipment industry which returned 20.3% over the past year.
Return vs Market: SENS underperformed the US Market which returned 30.3% over the past year.
Price Volatility
| SENS volatility | |
|---|---|
| SENS Average Weekly Movement | 10.4% |
| Medical Equipment Industry Average Movement | 8.2% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: SENS's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: SENS's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 132 | Tim Goodnow | www.senseonics.com |
Senseonics Holdings, Inc., a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company’s products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management. It serves healthcare providers and patients through a network of distributors and strategic fulfillment partners.
Senseonics Holdings, Inc. Fundamentals Summary
| SENS fundamental statistics | |
|---|---|
| Market cap | US$189.14m |
| Earnings (TTM) | -US$80.33m |
| Revenue (TTM) | US$22.21m |
8.5x
P/S Ratio-2.4x
P/E RatioIs SENS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SENS income statement (TTM) | |
|---|---|
| Revenue | US$22.21m |
| Cost of Revenue | US$24.53m |
| Gross Profit | -US$2.33m |
| Other Expenses | US$78.00m |
| Earnings | -US$80.33m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.13 |
| Gross Margin | -10.49% |
| Net Profit Margin | -361.77% |
| Debt/Equity Ratio | 262.9% |
How did SENS perform over the long term?
See historical performance and comparison